{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:47:01Z","timestamp":1793245621963,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41401-024-01381-x","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:05:37Z","timestamp":1725282337000},"page":"448-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-\u03b3 signaling"],"prefix":"10.1038","volume":"46","author":[{"given":"Fang-lin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-hua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-liang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-ling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-hua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ru","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-kun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301.","journal-title":"N Engl J Med"},{"key":"1381_CR2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"},{"key":"1381_CR3","first-page":"987","volume":"380","author":"P Schmid","year":"2019","unstructured":"Schmid P, Chui SY, Emens LA. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. reply. N Engl J Med. 2019;380:987\u20138.","journal-title":"N Engl J Med"},{"key":"1381_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"1381_CR5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2017;168:542.","journal-title":"Cell"},{"key":"1381_CR6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989\u20131004.","journal-title":"Immunity"},{"key":"1381_CR7","doi-asserted-by":"crossref","first-page":"19738","DOI":"10.18632\/oncotarget.7582","volume":"7","author":"F Passiglia","year":"2016","unstructured":"Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget. 2016;7:19738\u201347.","journal-title":"Oncotarget"},{"key":"1381_CR8","doi-asserted-by":"crossref","first-page":"a021881","DOI":"10.1101\/cshperspect.a021881","volume":"8","author":"M Namwanje","year":"2016","unstructured":"Namwanje M, Brown CW. Activins and inhibins: roles in development, physiology, and disease. Cold Spring Harb Perspect Biol. 2016;8:a021881.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1381_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/wdev.86","volume":"2","author":"A Weiss","year":"2013","unstructured":"Weiss A, Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol. 2013;2:47\u201363.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"1381_CR10","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1073\/pnas.92.15.6952","volume":"92","author":"F Pituello","year":"1995","unstructured":"Pituello F, Yamada G, Gruss P. Activin A inhibits Pax-6 expression and perturbs cell differentiation in the developing spinal cord in vitro. Proc Natl Acad Sci USA. 1995;92:6952\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1381_CR11","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/sj.onc.1205294","volume":"21","author":"L Bartholin","year":"2002","unstructured":"Bartholin L, Maguer-Satta V, Hayette S, Martel S, Gadoux M, Corbo L, et al. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene. 2002;21:2227\u201335.","journal-title":"Oncogene"},{"key":"1381_CR12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/bjc.2011.348","volume":"105","author":"H Kaneda","year":"2011","unstructured":"Kaneda H, Arao T, Matsumoto K, De Velasco MA, Tamura D, Aomatsu K, et al. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. Br J Cancer. 2011;105:1210\u20137.","journal-title":"Br J Cancer"},{"key":"1381_CR13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-2004-831901","volume":"22","author":"SJ Gregory","year":"2004","unstructured":"Gregory SJ, Kaiser UB. Regulation of gonadotropins by inhibin and activin. Semin Reprod Med. 2004;22:253\u201367.","journal-title":"Semin Reprod Med"},{"key":"1381_CR14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","volume":"147","author":"C Guignabert","year":"2023","unstructured":"Guignabert C, Savale L, Boucly A, Thuillet R, Tu L, Ottaviani M, et al. Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension. Circulation. 2023;147:1809\u201322.","journal-title":"Circulation"},{"key":"1381_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","volume":"80","author":"E Nunn","year":"2024","unstructured":"Nunn E, Jaiswal N, Gavin M, Uehara K, Stefkovich M, Drareni K, et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab. 2024;80:101880.","journal-title":"Mol Metab"},{"key":"1381_CR16","volume":"14","author":"K Shimizu","year":"2023","unstructured":"Shimizu K, Kikuta J, Ohta Y, Uchida Y, Miyamoto Y, Morimoto A, et al. Single-cell transcriptomics of human cholesteatoma identifies an activin A-producing osteoclastogenic fibroblast subset inducing bone destruction. Nat Commun. 2023;14:4417.","journal-title":"Nat Commun"},{"key":"1381_CR17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1084\/jem.176.5.1449","volume":"176","author":"M Eramaa","year":"1992","unstructured":"Eramaa M, Hurme M, Stenman UH, Ritvos O. Activin A\/erythroid differentiation factor is induced during human monocyte activation. J Exp Med. 1992;176:1449\u201352.","journal-title":"J Exp Med"},{"key":"1381_CR18","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2007-03-080994","volume":"111","author":"NC Robson","year":"2008","unstructured":"Robson NC, Phillips DJ, McAlpine T, Shin A, Svobodova S, Toy T, et al. Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood. 2008;111:2733\u201343.","journal-title":"Blood"},{"key":"1381_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cellimm.2008.11.001","volume":"255","author":"J Zhou","year":"2009","unstructured":"Zhou J, Tai G, Liu H, Ge J, Feng Y, Chen F, et al. Activin A down-regulates the phagocytosis of lipopolysaccharide-activated mouse peritoneal macrophages in vitro and in vivo. Cell Immunol. 2009;255:69\u201375.","journal-title":"Cell Immunol"},{"key":"1381_CR20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3389\/fimmu.2020.01641","volume":"11","author":"TN Hreha","year":"2020","unstructured":"Hreha TN, Collins CA, Daugherty AL, Griffith JM, Hruska KA, Hunstad DA. Androgen-influenced polarization of activin A-producing macrophages accompanies post-pyelonephritic renal scarring. Front Immunol. 2020;11:1641.","journal-title":"Front Immunol"},{"key":"1381_CR21","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/0008-5472.CAN-15-2668","volume":"76","author":"MR Shurin","year":"2016","unstructured":"Shurin MR, Ma Y, Keskinov AA, Zhao R, Lokshin A, Agassandian M, et al. BAFF and APRIL from activin A-treated dendritic cells upregulate the antitumor efficacy of dendritic cells In vivo. Cancer Res. 2016;76:4959\u201369.","journal-title":"Cancer Res"},{"key":"1381_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/2326-6066.CIR-19-0305","volume":"9","author":"M De Martino","year":"2021","unstructured":"De Martino M, Daviaud C, Diamond JM, Kraynak J, Alard A, Formenti SC, et al. Activin A promotes regulatory T-cell-mediated immunosuppression in irradiated breast cancer. Cancer Immunol Res. 2021;9:89\u2013102.","journal-title":"Cancer Immunol Res"},{"key":"1381_CR23","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.4049\/jimmunol.177.10.6787","volume":"177","author":"K Ogawa","year":"2006","unstructured":"Ogawa K, Funaba M, Chen Y, Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol. 2006;177:6787\u201394.","journal-title":"J Immunol"},{"key":"1381_CR24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2020.12.010","volume":"54","author":"B Wu","year":"2021","unstructured":"Wu B, Zhang S, Guo Z, Bi Y, Zhou M, Li P, et al. The TGF-beta superfamily cytokine activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. Immunity. 2021;54:308\u201323.e6.","journal-title":"Immunity"},{"key":"1381_CR25","doi-asserted-by":"crossref","first-page":"E2891","DOI":"10.1073\/pnas.1616942114","volume":"114","author":"S Tousa","year":"2017","unstructured":"Tousa S, Semitekolou M, Morianos I, Banos A, Trochoutsou AI, Brodie TM, et al. Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. Proc Natl Acad Sci USA. 2017;114:E2891\u2013E900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1381_CR26","volume":"2","author":"Z Yu","year":"2022","unstructured":"Yu Z, Cheng L, Liu X, Zhang L, Cao H. Increased expression of INHBA is correlated with poor prognosis and high immune infiltrating level in breast cancer. Front Bioinform. 2022;2:729902.","journal-title":"Front Bioinform"},{"key":"1381_CR27","volume":"12","author":"K Zhao","year":"2021","unstructured":"Zhao K, Yi Y, Ma Z, Zhang W. INHBA is a prognostic biomarker and correlated with immune cell infiltration in cervical cancer. Front Genet. 2021;12:705512.","journal-title":"Front Genet"},{"key":"1381_CR28","volume":"20","author":"X Li","year":"2020","unstructured":"Li X, Yu W, Liang C, Xu Y, Zhang M, Ding X, et al. INHBA is a prognostic predictor for patients with colon adenocarcinoma. BMC Cancer. 2020;20:305.","journal-title":"BMC Cancer"},{"key":"1381_CR29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2020.12.023","volume":"39","author":"H Lin","year":"2021","unstructured":"Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell. 2021;39:480\u201393.e6.","journal-title":"Cancer Cell"},{"key":"1381_CR30","doi-asserted-by":"crossref","first-page":"e004533","DOI":"10.1136\/jitc-2022-004533","volume":"10","author":"K Pinjusic","year":"2022","unstructured":"Pinjusic K, Dubey OA, Egorova O, Nassiri S, Meylan E, Faget J, et al. Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma. J Immunother Cancer. 2022;10:e004533.","journal-title":"J Immunother Cancer"},{"key":"1381_CR31","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"key":"1381_CR32","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u2013W14.","journal-title":"Nucleic Acids Res"},{"key":"1381_CR33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934\u201349.e16.","journal-title":"Cell"},{"key":"1381_CR34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.","journal-title":"Front Immunol"},{"key":"1381_CR35","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1073\/pnas.0610944104","volume":"104","author":"K Ramsauer","year":"2007","unstructured":"Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kroger A, Hauser H, et al. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene. Proc Natl Acad Sci USA. 2007;104:2849\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1381_CR36","first-page":"3399","volume":"61","author":"C Nakajima","year":"2001","unstructured":"Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res. 2001;61:3399\u2013405.","journal-title":"Cancer Res"},{"key":"1381_CR37","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.4049\/jimmunol.167.10.5574","volume":"167","author":"GZ Tau","year":"2001","unstructured":"Tau GZ, Cowan SN, Weisburg J, Braunstein NS, Rothman PB. Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells. J Immunol. 2001;167:5574\u201382.","journal-title":"J Immunol"},{"key":"1381_CR38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr.","year":"1994","unstructured":"Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415\u201321.","journal-title":"Science"},{"key":"1381_CR39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4049\/jimmunol.161.2.927","volume":"161","author":"CS Tannenbaum","year":"1998","unstructured":"Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol. 1998;161:927\u201332.","journal-title":"J Immunol"},{"key":"1381_CR40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI13543","volume":"108","author":"CH Kim","year":"2001","unstructured":"Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest. 2001;108:1331\u20139.","journal-title":"J Clin Invest"},{"key":"1381_CR41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15153","volume":"8","author":"E Latres","year":"2017","unstructured":"Latres E, Mastaitis J, Fury W, Miloscio L, Trejos J, Pangilinan J, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017;8:15153.","journal-title":"Nat Commun"},{"key":"1381_CR42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.131.2.788","volume":"131","author":"GH Wong","year":"1983","unstructured":"Wong GH, Clark-Lewis I, McKimm-Breschkin L, Harris AW, Schrader JW. Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. J Immunol. 1983;131:788\u201393.","journal-title":"J Immunol"},{"key":"1381_CR43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nri978","volume":"3","author":"S Gordon","year":"2003","unstructured":"Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23\u201335.","journal-title":"Nat Rev Immunol"},{"key":"1381_CR44","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4049\/jimmunol.157.4.1350","volume":"157","author":"LM Bradley","year":"1996","unstructured":"Bradley LM, Dalton DK, Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol. 1996;157:1350\u20138.","journal-title":"J Immunol"},{"key":"1381_CR45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0008-8749(88)90109-8","volume":"111","author":"JP Siegel","year":"1988","unstructured":"Siegel JP. Effects of interferon-gamma on the activation of human T lymphocytes. Cell Immunol. 1988;111:461\u201372.","journal-title":"Cell Immunol"},{"key":"1381_CR46","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.","journal-title":"Sci Transl Med"},{"key":"1381_CR47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397\u2013404.e9.","journal-title":"Cell"},{"key":"1381_CR48","volume":"11","author":"XD Liu","year":"2020","unstructured":"Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11:2135.","journal-title":"Nat Commun"},{"key":"1381_CR49","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","volume":"6","author":"R Sabatier","year":"2015","unstructured":"Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449\u201364.","journal-title":"Oncotarget"},{"key":"1381_CR50","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang B, Liu Y, Zhou S, Jiang H, Zhu K, Wang R. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Int Immunopharmacol. 2020;80:106214.","journal-title":"Int Immunopharmacol"},{"key":"1381_CR51","volume":"4","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, et al. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell Rep Med. 2023;4:101214.","journal-title":"Cell Rep Med"},{"key":"1381_CR52","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jid.2017.07.845","volume":"137","author":"P Donovan","year":"2017","unstructured":"Donovan P, Dubey OA, Kallioinen S, Rogers KW, Muehlethaler K, M\u00fcller P, et al. Paracrine activin-A signaling promotes melanoma growth and metastasis through immune evasion. J Invest Dermatol. 2017;137:2578\u201387.","journal-title":"J Invest Dermatol"},{"key":"1381_CR53","doi-asserted-by":"crossref","first-page":"e003521","DOI":"10.1136\/jitc-2021-003521","volume":"9","author":"R Reschke","year":"2021","unstructured":"Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021;9:e003521.","journal-title":"J Immunother Cancer"},{"key":"1381_CR54","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1172\/JCI120358","volume":"128","author":"Y Zohar","year":"2018","unstructured":"Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest. 2018;128:1200\u20131.","journal-title":"J Clin Invest"},{"key":"1381_CR55","doi-asserted-by":"crossref","first-page":"e1091554","DOI":"10.1080\/2162402X.2015.1091554","volume":"5","author":"ZQ Liu","year":"2016","unstructured":"Liu ZQ, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology. 2016;5:e1091554.","journal-title":"Oncoimmunology"},{"key":"1381_CR56","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6509","volume":"7","author":"R Reschke","year":"2022","unstructured":"Reschke R, Gajewski TF. CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022;7:eabq6509.","journal-title":"Sci Immunol"},{"key":"1381_CR57","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"HD Tang","year":"2018","unstructured":"Tang HD, Liang Y, Anders RA, Taube JM, Qiu XY, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580\u20138.","journal-title":"J Clin Invest"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01381-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01381-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T16:13:06Z","timestamp":1737389586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01381-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1038\/s41401-024-01381-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}